Prognostic, Clinicopathological, and Function of Key Cuproptosis Regulator FDX1 in Clear Cell Renal Cell Carcinoma

Clear cell renal cell carcinoma (ccRCC) is the most common histological subtype of renal cancer. Cuproptosis is suggested to be a novel therapy target for cancer treatment. However, the function of cuproptosis and its key regulator FDX1 in ccRCC remains unclear. In this study, we adequately explored the prognostic factors, clinicopathological characteristics, and function of FDX1 in ccRCC. We found that the expression of FDX1 was significantly downregulated in ccRCC samples. Patients with a higher FDX1 expression had a significantly better prognosis, including overall survival (OS) (Hazard ratio (HR): 2.54, 95% confidence interval (CI): 1.82–3.53, p < 0.001), disease-specific survival (DSS) (HR: 3.04, 95% CI: 2.04–4.54, p < 0.001), and progression-free survival (PFS) (HR: 2.54, 95% CI: 1.82–3.53, p < 0.001). FDX1 was a clinical predictor to stratify patients into the high or low risk of poor survival, independent of conventional clinical features, with the area under the ROC curve (AUC) of 0.658, 0.677, and 0.656 for predicting the 5-year OS, DSS, and PFS. The nomogram model based on FDX1 had greater predictive power than other individual prognostic parameters. FDX1 mainly participated in the oxidative-related process and mitochondrial respiration-related processes but was not associated with immune infiltration levels. In conclusion, the cuproptosis key regulator FDX1 could serve as a potential novel prognostic biomarker for ccRCC patients.

[1]  L. Bu,et al.  Cuproptosis: lipoylated TCA cycle proteins-mediated novel cell death pathway , 2022, Signal Transduction and Targeted Therapy.

[2]  Lingmin Xie,et al.  A Novel Cuproptosis-Related Prognostic Gene Signature and Validation of Differential Expression in Clear Cell Renal Cell Carcinoma , 2022, Genes.

[3]  T. Golub,et al.  Copper induces cell death by targeting lipoylated TCA cycle proteins , 2022, Science.

[4]  V. Oliveri.  Selective Targeting of Cancer Cells by Copper Ionophores: An Overview , 2022, Frontiers in Molecular Biosciences.

[5]  U. Capitanio,et al.  European Association of Urology Guidelines on Renal Cell Carcinoma: The 2022 Update. , 2022, European urology.

[6]  Zhaohui S. Qin,et al.  UALCAN: An update to the integrated cancer data analysis platform , 2022, Neoplasia.

[7]  A. Casini,et al.  Connecting copper and cancer: from transition metal signalling to metalloplasia , 2021, Nature Reviews Cancer.

[8]  Changzhu Duan,et al.  FDX1 can Impact the Prognosis and Mediate the Metabolism of Lung Adenocarcinoma , 2021, Frontiers in Pharmacology.

[9]  A. Elorza,et al.  Role of Copper on Mitochondrial Function and Metabolism , 2021, Frontiers in Molecular Biosciences.

[10]  M. Zhang,et al.  A Novel Ferroptosis-Related Gene Model for Overall Survival Predictions of Bladder Urothelial Carcinoma Patients , 2021, Frontiers in Oncology.

[11]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[12]  W. Rathmell,et al.  Clear cell renal cell carcinoma ontogeny and mechanisms of lethality , 2020, Nature Reviews Nephrology.

[13]  S. Moore,et al.  Getting out what you put in: copper in mitochondria and its impacts on human disease. , 2020, Biochimica et biophysica acta. Molecular cell research.

[14]  H. Tian,et al.  Transition metal chelators, pro-chelators, and ionophores as small molecule cancer chemotherapeutic agents. , 2020, Chemical Society reviews.

[15]  G. Weisman,et al.  Metallothioneins regulate ATP7A trafficking and control cell viability during copper deficiency and excess , 2020, Scientific Reports.

[16]  S. Zeng,et al.  Identification of a three-long noncoding RNA prognostic model involved competitive endogenous RNA in kidney renal clear cell carcinoma , 2020, Cancer Cell International.

[17]  T. Golub,et al.  Mitochondrial metabolism promotes adaptation to proteotoxic stress , 2019, Nature Chemical Biology.

[18]  Zemin Zhang,et al.  GEPIA2: an enhanced web server for large-scale expression profiling and interactive analysis , 2019, Nucleic Acids Res..

[19]  B. Rini,et al.  Treatment of renal cell carcinoma: Current status and future directions , 2017, CA: a cancer journal for clinicians.

[20]  Jun S. Liu,et al.  TIMER: A Web Server for Comprehensive Analysis of Tumor-Infiltrating Immune Cells. , 2017, Cancer research.

[21]  Zhongheng Zhang,et al.  Drawing Nomograms with R: applications to categorical outcome and survival data. , 2017, Annals of translational medicine.

[22]  Cheri M Ackerman,et al.  Analytical Methods for Imaging Metals in Biology: From Transition Metal Metabolism to Transition Metal Signaling. , 2017, Analytical chemistry.

[23]  Martin D de Jonge,et al.  Imaging metals in biology: balancing sensitivity, selectivity and spatial resolution. , 2015, Chemical Society reviews.

[24]  A. Hauschild,et al.  Final results of phase III SYMMETRY study: randomized, double-blind trial of elesclomol plus paclitaxel versus paclitaxel alone as treatment for chemotherapy-naive patients with advanced melanoma. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  E. Elkin,et al.  Decision Curve Analysis: A Novel Method for Evaluating Prediction Models , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.

[26]  Pablo Tamayo,et al.  Gene set enrichment analysis: A knowledge-based approach for interpreting genome-wide expression profiles , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  T. Lumley,et al.  Time‐Dependent ROC Curves for Censored Survival Data and a Diagnostic Marker , 2000, Biometrics.

[28]  S. Kaler,et al.  ATP7A-related copper transport diseases—emerging concepts and future trends , 2011, Nature Reviews Neurology.